Hispanic Recruitment It’s no surprise to Gabriel S. Galindo that many Hispanics and Latinos in the United States are reluctant to sign up for medical research trials. It’s hard enough getting them to go to the doctor, he said. His own grandmother di ...
New Approaches to Virtual Screening Article taken from http://www.dddmag.com/articles/2013/12/new-approaches-virtual-screening#at_pco=smlwn-1.0&at_si=5550cf7acc33acc1&at_ab=per-2&at_pos=0&at_tot=1 Ivan Solt, Anna Tomin, Krisztian N ...
Hepatitis C Therapy Clears Virus in 93% of Patients in BMS-Funded Trial Article taken from: http://www.dddmag.com/articles/2015/05/hepatitis-c-therapy-clears-virus-93-patients-bms-funded-trial?et_cid=4553431&et_rid=745476040&type=headline I ...
For the first time, it has been shown that many mutations in tumors--20 percent—are immunogenic, or able to rouse armies of T cells, post-vaccine. Also for the first time, it has been shown that most of those roused T cell armies are helper CD4+ T ce ...
Gov. Jerry Brown is launching a statewide initiative with the University of California, to advance the field of precision medicine. The effort will involve collaborating with other academic and industry partners and starting to build the infrastruct ...
Every day in hospitals around the world, patients suffer painful allergic reactions to the medicines they are given. The reactions, known as pseudo-allergies, often cause patients to endure itchiness, swelling and rashes as an unwanted part of their ...
The drugs were designed to keep cancer cells at bay by preventing their growth, survival and spread. Yet, after clinical trials, they left scientists scratching their heads and drug developers watching their investments succumb to cancer’s latest tr ...
Nanoparticle drugs—tiny containers packed with medicine and with the potential to be shipped straight to tumors—were thought to be a possible silver bullet against cancer. However new cancer drugs based on nanoparticles have not improved overall sur ...
Federal health experts have unanimously endorsed a Novartis drug which is expected to become the first lower-cost copy of a biotech drug to reach the U.S. market. A panel of Food and Drug Administration experts ruled that the company's version of N ...
Vanderbilt University researcher William Mitchell, M.D., Ph.D., and colleagues in Germany and Canada have demonstrated a method for detecting “cell-free” tumor DNA in the bloodstream. Mitchell believes the technique will be transformative in provid ...
